Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.03
MACK's Cash to Debt is ranked higher than
54% of the 1443 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. MACK: 1.03 )
MACK' s 10-Year Cash to Debt Range
Min: 1.03   Max: 1051.13
Current: 1.03

1.03
1051.13
Equity to Asset -0.64
MACK's Equity to Asset is ranked lower than
52% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MACK: -0.64 )
MACK' s 10-Year Equity to Asset Range
Min: -3.82   Max: -0.04
Current: -0.64

-3.82
-0.04
F-Score: 5
Z-Score: -3.34
M-Score: -4.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -64.48
MACK's Operating margin (%) is ranked higher than
74% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -95.34 vs. MACK: -64.48 )
MACK' s 10-Year Operating margin (%) Range
Min: -2220.11   Max: -64.48
Current: -64.48

-2220.11
-64.48
Net-margin (%) -81.06
MACK's Net-margin (%) is ranked higher than
72% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -77.05 vs. MACK: -81.06 )
MACK' s 10-Year Net-margin (%) Range
Min: -2284.59   Max: -81.06
Current: -81.06

-2284.59
-81.06
ROA (%) -49.91
MACK's ROA (%) is ranked higher than
61% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. MACK: -49.91 )
MACK' s 10-Year ROA (%) Range
Min: -110.9   Max: -47.45
Current: -49.91

-110.9
-47.45
ROC (Joel Greenblatt) (%) -475.37
MACK's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 1411 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. MACK: -475.37 )
MACK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1483.52   Max: -475.53
Current: -475.37

-1483.52
-475.53
Revenue Growth (3Y)(%) -31.30
MACK's Revenue Growth (3Y)(%) is ranked higher than
62% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. MACK: -31.30 )
MACK' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -31.3
Current: -31.3

EBITDA Growth (3Y)(%) -55.30
MACK's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 828 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. MACK: -55.30 )
MACK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -32.8
Current: -55.3

EPS Growth (3Y)(%) -51.40
MACK's EPS Growth (3Y)(%) is ranked higher than
54% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. MACK: -51.40 )
MACK' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -33.8
Current: -51.4

» MACK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MACK Guru Trades in Q1 2014

Murray Stahl 12,000 sh (New)
» More
Q2 2014

MACK Guru Trades in Q2 2014

Paul Tudor Jones 13,622 sh (New)
Jim Simons 569,413 sh (New)
Murray Stahl 12,000 sh (unchged)
» More
Q3 2014

MACK Guru Trades in Q3 2014

Murray Stahl 12,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 321,213 sh (-43.59%)
» More
Q4 2014

MACK Guru Trades in Q4 2014

Paul Tudor Jones 12,196 sh (New)
Murray Stahl 12,000 sh (unchged)
Jim Simons 255,413 sh (-20.48%)
» More
» Details

Insider Trades

Latest Guru Trades with MACK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 476.19
MACK's Forward P/E is ranked higher than
89% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MACK: 476.19 )
N/A
P/S 13.64
MACK's P/S is ranked higher than
73% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 37.64 vs. MACK: 13.64 )
MACK' s 10-Year P/S Range
Min: 1.79   Max: 16.53
Current: 13.64

1.79
16.53
Current Ratio 1.19
MACK's Current Ratio is ranked higher than
52% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.39 vs. MACK: 1.19 )
MACK' s 10-Year Current Ratio Range
Min: 0.73   Max: 3.33
Current: 1.19

0.73
3.33
Quick Ratio 1.19
MACK's Quick Ratio is ranked higher than
55% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. MACK: 1.19 )
MACK' s 10-Year Quick Ratio Range
Min: 0.73   Max: 3.33
Current: 1.19

0.73
3.33
Days Sales Outstanding 11.77
MACK's Days Sales Outstanding is ranked higher than
96% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. MACK: 11.77 )
MACK' s 10-Year Days Sales Outstanding Range
Min: 11.77   Max: 300.77
Current: 11.77

11.77
300.77

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.40
MACK's Price/Median PS Value is ranked higher than
82% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. MACK: 1.40 )
MACK' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 1.19
Current: 1.4

0.47
1.19
Earnings Yield (Greenblatt) -4.80
MACK's Earnings Yield (Greenblatt) is ranked higher than
70% of the 1398 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. MACK: -4.80 )
MACK' s 10-Year Earnings Yield (Greenblatt) Range
Min: -8.5   Max: 0
Current: -4.8

-8.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:MP6.Germany,
Merrimack Pharmaceuticals Inc was incorporated in the Commonwealth of Massachusetts in 1993 and reincorporated under the laws of the State of Delaware in October 2010. The Company is a biopharmaceutical company engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer. Its core approach to systems biology is to apply multidisciplinary and multi technology capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks, that allow to engineer treatments that are directed at the mechanisms of disease. The Company currently has six targeted therapeutic oncology candidates in clinical development, are either monoclonal antibodies or monoclonal antibody-derived molecules that are designed to block oncogenic signaling pathways, such as MM-121, MM-111, MM-151 and MM-141, or nanotherapeutics, such as MM-398 and MM-302, that are designed to preferentially deliver cytotoxic therapies to the tumor tissue. MM-398 is a novel, stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 is designed to stably retain and protect irinotecan while in circulation in the body and enable efficient accumulation of the drug in solid tumors. Its Phase 3 clinical trial of MM-398 is focused on pancreatic cancer, and used in a number of other solid tumor indications, including colorectal cancer, lung cancer, breast cancer, glioma and pediatric solid tumors. Its MM-121 is a fully human monoclonal antibody that targets the ErbB3 cell surface receptor. MM-121 is designed to inhibit cancer growth directly, restore a tumor's sensitivity to drugs to which it has become resistant, and delay the development of resistance by a tumor to other agents. Its MM-111 is a bispecific antibody designed to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 (HER2) cell surface receptor. MM-111 is designed to anchor to both receptors, ErbB2 (HER2) and HER3, on the cell surface and block heregulin's ability to transmit tumor growth signals, thus inhibiting the tumor cell's ability to thrive. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. It is designed to target and bind to cancer cells that overexpress ErbB2 (HER2) and thereby release doxorubicin at the site of the tumor, while minimizing uptake into normal cells, including those of the heart. MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of EGFR (ErbB1). MM-151 is in its Phase 1 clinical trial for patients with refractory solid tumors. Its MM-141 is a fully human tetravalent bispecific antibody designed to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth
» More Articles for MACK

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Starbucks Corp, KD Supply Holdings Inc, Capital One Financial Corp, Merr Dec 14 2014 

More From Other Websites
First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients Apr 21 2015
First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients Apr 21 2015
Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in... Apr 20 2015
Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in... Apr 20 2015
We're diversified and robust: Merrimack CEO Apr 01 2015
Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer... Mar 26 2015
Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer... Mar 26 2015
MERRIMACK PHARMACEUTICALS INC Financials Mar 06 2015
MERRIMACK PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 27 2015
Merrimack Pharmaceuticals Q4 Loss Narrower Than Expected - Analyst Blog Feb 27 2015
Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results Feb 26 2015
Merrimack reports 4Q loss Feb 26 2015
Merrimack reports 4Q loss Feb 26 2015
Merrimack Pharmaceuticals' (MACK) Loss Narrows in Q4 - Tale of the Tape Feb 26 2015
MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 26 2015
Q4 2014 Merrimack Pharmaceuticals Inc Earnings Release - Before Market Open Feb 26 2015
Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results Feb 26 2015
Merrimack Pharmaceuticals (MACK): A Miss this Earnings? - Analyst Blog Feb 24 2015
Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of... Feb 19 2015
Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of... Feb 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK